Please login to the form below

Not currently logged in
Email:
Password:

Remdesivir

This page shows the latest Remdesivir news and features for those working in and with pharma, biotech and healthcare.

Abivax doses first patient in phase 2b/3 COVID-19 clinical trial

Abivax doses first patient in phase 2b/3 COVID-19 clinical trial

Despite these results, there is still a focus on the use of anti-inflammatories as a treatment for COVID-19, with Gilead planning combination studies of its anti-viral drug remdesivir

Latest news

More from news
Approximately 8 fully matching, plus 11 partially matching documents found.

Latest Intelligence

  • Working together against COVID-19 Working together against COVID-19

    Gilead shared some positive updates on social media about remdesivir but did not address all HCP concerns. ... Subsequently, Gilead dropped remdesivir’s orphan drug designation based on its potential as a coronavirus treatment.

  • COVID-19: the race to find a vaccine COVID-19: the race to find a vaccine

    A subsequent leak about the apparent failure of remdesivir in a Chinese trial then dampened expectations again. ... Yet, it is unlikely that any of the drugs will be a panacea, with Jefferies analysts saying remdesivir “might be modestly helpful”.

  • As COVID-19 takes over the world, biopharma fights back As COVID-19 takes over the world, biopharma fights back

    An experimental antiviral: Gilead’s remdesivir. Gilead’s remdesivir, an experimental antiviral drug, is arguably the most-talked about potential treatment for COVID-19. ... Lane is currently overseeing ongoing studies at the US National Institutes of

More from intelligence
Approximately 0 fully matching, plus 3 partially matching documents found.

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
Life Healthcare Communications

Life is a creative communications agency offering multi-channel solutions for the healthcare industry. We use a storytelling approach to turn...

Latest intelligence

The search for treatments for Parkinson’s disease
The research requires resilience but pharma is urged to ‘keep innovating, keep trying’...
Margot Hannah, OPEN Health - A personal perspective of LGBT+ and diversity.
Ditch the Label – it’s just me....
The impact of COVID-19 on clinical trials
As all industry sectors work to assess both the impact and the optimal path forward, the effects are expected to be diverse and long-lasting...

Infographics